Eagle Pharmaceuticals, Inc. (EGRX) Stock Forecast
EGRX analyst forecast
as of October 21, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $17.00 average of analyst targets
- Upside to target
- +332.0% from the latest close
- Next earnings
- —
- 52-week range
- $0.00 – $3.94
EGRX analyst ratings
1 analystsNumber of analysts at each rating.
EGRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
EGRX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; EGRX beat in 6 of 12.
What analysts expect from EGRX
1 analysts cover Eagle Pharmaceuticals; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $17.00, 332.0% above the latest close of $3.94. Eagle Pharmaceuticals beat the EPS estimate in 6 of the last 12 quarters.
Related: EGRX income statement, EGRX key metrics, EGRX chart. See the EGRX stock overview for the latest quote and news.
EGRX forecast FAQ
What is Eagle Pharmaceuticals's price target?
The average analyst price target for Eagle Pharmaceuticals is $17.00, 332.0% above the latest close of $3.94.
Is Eagle Pharmaceuticals a buy, hold or sell?
Of 1 analysts covering Eagle Pharmaceuticals, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
Does Eagle Pharmaceuticals usually beat earnings estimates?
Eagle Pharmaceuticals reported EPS at or above the analyst estimate in 6 of the last 12 quarters.